Intensity Therapeutics, Inc. INTS
2.46 USD -0.08 (-3.15%)
As ofNov 20, 2026, 2:48 PM EST
2.28 Day range 2.48
2.28 52-week range 15.00
- YTD
- -76.00%
- 1 year
- -74.11%
News
benzinga.com StoneX Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $8 StoneX analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $12 to $8.
benzinga.com Intensity Therapeutics Q3 2026 Earnings Call Transcript Intensity Therapeutics (NASDAQ:INTS) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Intensity Therapeutics Q3 EPS $(1.09) Misses $(0.99) Estimate. Cash and Equivalents $8.5M Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.99) by 10.1 percent. This is a 172.67 percent decrease over…
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…benzinga.com Intensity Therapeutics To Present Data For First Seven Participants In Group A In INVINCIBLE-4 Trial In ePoster By The Swiss Cancer Institute At ESMO 2026 Virtual Congress Platform Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using…
